Correction: The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks

Frederick A. Sirgel; Robin M. Warren; Erik C. Böttger; Marisa Klopper; Thomas C. Victor; Paul D. van Helden

PMC · DOI:10.1371/journal.pone.0134190·July 21, 2015

Correction: The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks

Frederick A. Sirgel, Robin M. Warren, Erik C. Böttger, Marisa Klopper, Thomas C. Victor, Paul D. van Helden

PDF

Open Access

Abstract

Linked entities

Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.

Genes1

rpoB

Proteins1

Species1

Mycobacterium tuberculosis(species)

Chemicals2

Rifabutin Rifampicin

Diseases2

Tuberculosis MDR

Mutations6

D516YD516SS531LD516VQ510PD516T

Figures1

Click any figure to enlarge with its caption.

Peer Reviews

No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.

Videos

No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.

Taxonomy

TopicsTuberculosis Research and Epidemiology · Mycobacterium research and diagnosis · Diagnosis and treatment of tuberculosis

Full text

There is an error in Table 1. An AspTyr mutation is wrongly abbreviated as D516T (1). It should be listed as D516Y (1). Please see the corrected Table 1 here.

Bibliography1

The reference list from the paper itself. Each links out to its DOI / PubMed record.

1Sirgel FA, Warren RM, Böttger EC, Klopper M, Victor TC, van Helden PD (2013) The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks. P Lo S ONE 8(3): e 59414 doi:10.1371/journal.pone.0059414 2352718910.1371/journal.pone.0059414 PMC 3602005 · doi ↗ · pubmed ↗